企展控股(01808.HK)2024年財報亮眼:收益增長574%,軟件硬件業務顯著增長
格隆匯3月21日丨企展控股(01808.HK)發佈公吿,截至2024年12月31日止年度,實現收益4.09億元人民幣,同比增加573.7%;毛利為4601.4萬元人民幣,同比增加76.7%;公司權益持有人應占溢利7273.7萬元人民幣,同比增加1210.6%;基本每股盈利人民幣0.321元。
2024年年,受惠於管理方面的全面改善,軟件及硬件業務於2024年較2023年顯著增長。軟件及硬件業務整體收益大幅增加,主要由於集團持續發展現有業務,以及訂立及完成涉及綜合資訊科技解決方案、邊緣計算、智算等數據服務的新合約所致。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.